SAR-443809
Based on 1 Customer Validation
SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 97.06%
- 분자량:144.13 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
SAR-443809 selectively binds to human factor Bb (EC50 = 30.9 ng/mL) and shows no specific binding to other tested plasma serine proteases, including most complement system enzymes[1].
SAR-443809 (50 minutes at 37°C) inhibits alternative pathway-mediated hemolysis of rabbit erythrocytes with an IC50 of 28.45 μg/mL[1].
SAR-443809 (50 minutes at 37°C) inhibits alternative pathway-mediated C3b deposition on rabbit erythrocytes with an apparent IC50 of 33.8 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys (female)[1]
-
Dosage:15 mg/kg (i.v.); 15 mg/kg (s.c.)
-
Administration:i.v.; single dose
s.c.; single dose -
Result:Achieved 90% inhibition of alternative pathway complement activity at 24 hours post-dose, sustained for at least 288 hours (i.v.).
Reached 90% inhibition of alternative pathway complement activity between 24-48 hours post-dose, sustained for at least 288 hours (s.c.).
Showed no classical pathway inhibition.
Gene ID
Accession
AAH04143.1
Target
Complement Factor B/CFB
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded SAR-443809 on biosensor, can bind Complement Factor B/CFB Protein, Human (HEK293, HY-P7813) with an affinity constant of 1.18E-08 M as determined in BLI assay.
Chemical Information
-
Appearance Liquid
-
분자량 144.13 kDa
-
Color Colorless to light yellow
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SAR-443809 Related Classifications
HY-P992456 Related Classifications
Powered by Bioz